Atezolizumab plus bevacizumab combination for untreated metastatic kidney cancer
Results from this phase III trial of atezolizumab plus bevacizumab [...]
Avelumab plus axitinib granted FDA approval for advanced kidney cancer
The Food and Drug Administration (FDA) in the United States [...]
Effect of treatment delay on outcomes in metastatic kidney cancer
A recent study published in Science Direct followed patients with [...]
Targeted therapies with immunotherapies in kidney cancer
The following video is an interview with Professor Thomas Powles [...]
Pembrolizumab plus axitinib granted FDA approval for advanced kidney cancer
The Food and Drug Administration (FDA) in the United States [...]
Dalantercept plus axitinib combination for advanced kidney cancer
The results from a recent phase II study comparing a [...]
HIF-2α inhibitor shows promise in patients with advanced kidney cancer
A recent phase I/II clinical trial with PT2977, a hypoxia-inducible [...]
Bevacizumab plus erlotinib combination for advanced HLRCC
A recent study, published in Cancer Research and Treatment in [...]
Hand-foot syndrome as a predictor of better outcomes in patients treated with sunitinib
A recent study, published in the journal Advances in Medicine [...]
ASCO GU 2019: Avelumab plus axitinib combination superior to sunitinib
The results from the following study were presented at the [...]
